Compositions and Methods for Treating Metabolic Disorders

An expression vector comprising a Cela2a polynucleotide.

A therapeutic composition comprising a Cela2a polypeptide or polynucleotide in an intracellular delivery vehicle.

A method of altering glucose or lipid metabolism in a subject, the method comprising administering to the subject an effective amount of a composition comprising a Cela2a polypeptide or polynucleotide, thereby altering glucose or lipid metabolism in the subject.

A method of treating atherosclerosis, diabetes, hypertension, or hypertriglyceridemia in a subject, the method comprising administering to the subject an effective amount of a composition comprising a Cela2a polypeptide or polynucleotide, thereby treating atherosclerosis, diabetes, hypertension, or hypertriglyceridemia in the subject.

A kit comprising a capture reagent that binds a Cela2a polypeptide or polynucleotide.

A method of detecting atherosclerosis and/or diabetes in a subject, the method comprising

• measuring a level or a sequence of a Cela2a polypeptide or polynucleotide in a biological sample from the subject relative to a reference sequence,
• wherein a decreased level of the Cela2a polypeptide or polynucleotide or presence of a mutation in the Cela2a polypeptide or polynucleotide sequence indicates presence of atherosclerosis and/or diabetes in the subject.

A method of identifying a subject at risk of developing atherosclerosis and/or diabetes, the method comprising

• measuring a level or a sequence of a Cela2a polypeptide or polynucleotide in a biological sample from the subject relative to a reference level or reference sequence,
• wherein a decreased level of the Cela2a polypeptide or polynucleotide or presence of a mutation in the Cela2a polypeptide or polynucleotide sequence indicates the subject is at risk of developing atherosclerosis and/or diabetes.

A method of treating atherosclerosis and/or diabetes in a subject, the method comprising

• administering to the subject an effective amount of a Cela2a polypeptide, wherein the subject is pre-selected as having a mutation in a Cela2a polypeptide or polynucleotide relative to a reference sequence or a decreased level of a Cela2a polypeptide relative to a reference level,
• thereby treating atherosclerosis and/or diabetes in the subject.

A method of producing a Cela2a polypeptide, the method comprising

• (a) expressing a recombinant Cela2a polypeptide in a host cell, and
• (b) isolating the recombinant Cela2a polypeptide.